Curated regulatory guidance, clinical analyses, and market reports. AI-summarized, editor-reviewed, instantly downloadable.
Research Pulse
Aggregated from live regulatory feedsNovaPharmaNews hosts 68 curated pharmaceutical whitepapers and industry reports from 8 publishers — FDA and EMA regulatory guidance, clinical analyses, manufacturing intelligence, and market research. 3 featured reports are editor-picked this week. Each landing page includes key takeaways, optional PDF download, and links to related drugs, companies, and pipeline data.
Methodology & data sources Publications & analysis Editorial policy
🔒 ★ Optimizing Pharmaceutical Manufacturing: The Critical Role of Dew Point Monitoring
Dew point monitoring is crucial for controlling humidity in sensitive industrial environments where even trace moisture can compromise produ…
🔒 ★ Pharma R&D ROI: A Multidimensional Framework for AI Investment Success
Top pharma companies are adopting a multidimensional ROI framework that combines scientific, operational, and commercial metrics to evaluate…
🔒 ★ Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials
IRBs provide an independent, ethics-focused evaluation of proposed research, including checks on clinical investigators' potential biases ( …
🔒 ★ Optimizing Pharmaceutical Manufacturing: The Critical Role of Dew Point Monitoring
Dew point monitoring is crucial for controlling humidity in sensitive industrial environments where even trace moisture can compromise produ…
🔒 ★ Pharma R&D ROI: A Multidimensional Framework for AI Investment Success
Top pharma companies are adopting a multidimensional ROI framework that combines scientific, operational, and commercial metrics to evaluate…
🔒 ★ Navigating Human Research: Mass General Brigham's IRB Guidance for Ethical Clinical Trials
IRBs provide an independent, ethics-focused evaluation of proposed research, including checks on clinical investigators' potential biases ( …
🔒 ★ National Drug Control Strategy (2026): A Comprehensive Approach to Combat Drug Addiction
The strategy addresses the fentanyl crisis as a national emergency.
★ FDA Seeks Input on Drug Repurposing for Unmet Medical Needs
FDA opened public docket FDA-2026-N-4492 to gather input on repurposing approved drugs with limited commercial interest for unmet medical ne…
🔒 ★ European Medicines Agency Pre-Authorisation Procedural Advice
Guidance on procedural advice for users of the centralised procedure by the European Medicines Agency.
🔒 PDF Innovation Development and Access pathway
IDAP is a holistic framework spanning four linked phases: Research and Development; regulatory processes and product registration; listing, …
🔒 EFPIA W.A.I.T Indicator 2026: 597-day waits
Full availability on public reimbursement lists stands at 28%, down from 29% in the 2024 study, indicating a declining trend in unrestricted…
🔒 IFPMA whitepaper: How assessment reports enable regulatory reliance in pharma
Regulatory reliance helps NRAs avoid duplicative reviews and allocate resources more efficiently by leveraging prior scientific evaluations …
🔒 EMA 2025 Annual Report Annexes: Committees, Opinions, and Governance
The document comprises 24 annexes documenting EMA committee memberships, 2025 scientific opinions, and regulatory decisions across human and…
🔒 Integrated delivery networks in Middle East healthcare: what PwC says about the next phase of care
Scale creates value only when healthcare assets are connected through shared systems, referral flows and coordinated management disciplines
🔒 Healthcare investment in Central and Eastern Europe: what pharma teams should know
CEE governments invested an average of 5.47% of GDP in healthcare in 2023, compared with 8.17% in the EU4 (Germany, France, Italy, Spain). T…
🔒 EFPIA on Harmonising Pharmaceutical Product Carbon Footprints with PAS 2090
Pharmaceutical product carbon footprint (PCF) and life cycle assessment (LCA) reporting currently lacks harmonised, sector-specific standard…
🔒 EFPIA analysis: biopharmaceutical strategies in 10 countries and what Europe can learn
Biotech and biopharma are now embedded in national security and competitiveness frameworks; policy support spans research, startups, manufac…
🔒 America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
Small and mid-sized biotechs represent approximately 99% of U.S. biotech business establishments and account for 71% of total industry emplo…
🔒 FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
FDA CBER held a dedicated patient listening meeting focused on two core themes: safety considerations in gene therapy treatment decisions an…
🔒 BIO 2025 Report: U.S. Bioscience Industry Policy Guide for State Growth
States are adopting phase-specific policy approaches tailored to company development stage, from discovery and seed through commercializatio…
🔒 EFPIA report: economic impact of industry clinical trials across Europe
Industry clinical trials created €10.1 billion in direct GVA and €21.7 billion in total GVA across the EEA in 2025, accounting for indirect …
Entity directories linked from research reports and market briefs.
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
New reports are ingested daily from leading publishers and regulatory sources. Featured picks highlight high-impact FDA, EMA, and industry research each week.